Ozuriftamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Oropharyngeal Cancer. According to Globaldata, it is involved in 6 clinical trials, of which 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ozuriftamab vedotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ozuriftamab vedotin is expected to reach an annual total of $87 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Ozuriftamab vedotin Overview
BA-3021 is under development for the treatment of solid tumors include unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), melanoma, metastatic melanoma, pancreatic cancer, colorectal cancer, rectal carcinoid tumor, head and neck cancer, soft tissue sarcoma (STS), ovarian cancer, fallopian tube cancer, peritoneal cancer, recurrent or metastatic squamous cell carcinoma of the head and neck, oropharynx, oral cavity, hypopharynx, and larynx cancer. The drug candidate acts by targeting the cells expressing tyrosine-protein kinase transmembrane receptor (ROR2). It is developed based on conditionally active biologics (CAB) platform. It is administered through intravenous route.
BioAtla is a clinical-stage biopharmaceutical company that focused on on developing antibody-based therapeutics for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is protein kinase receptor. Its BA3021 is developing a CAB antibody drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. The company offers laboratories in the US and China. BioAtla is headquartered in San Diego, California, the US.
The operating loss of the company was US$108.1 million in FY2022, compared to an operating loss of US$95.8 million in FY2021. The net loss of the company was US$106.5 million in FY2022, compared to a net loss of US$95.4 million in FY2021.
For a complete picture of Ozuriftamab vedotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.